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BACKGROUND: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature
retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the
use of this assay to predict neoadjuvant chemotherapy response in early breast cancer.
METHODS: This feasibility study assessed the integration of a novel biomarker into clinical workflows. Tumour samples were
collected from patients receiving standard of care neoadjuvant chemotherapy (FEC+ /−taxane and anti-HER2 therapy as
appropriate) at baseline, mid- and post-chemotherapy. Baseline DDIR signature scores were correlated with pathological treatment
response. RNA sequencing was used to assess chemotherapy/response-related changes in biologically linked gene signatures.
RESULTS: DDIR signature reports were available within 14 days for 97.8% of 46 patients (13 TNBC, 16 HER2+ ve, 27 ER+ HER2-ve).
Positive scores predicted response to treatment (odds ratio 4.67 for RCB 0-1 disease (95% CI 1.13–15.09, P= 0.032)). DDIR positivity
correlated with immune infiltration and upregulated immune-checkpoint gene expression.
CONCLUSIONS: This study validates the DDIR signature as predictive of response to neoadjuvant chemotherapy which can be
integrated into clinical workflows, potentially identifying a subgroup with high sensitivity to anthracycline chemotherapy.
Transcriptomic data suggest induction with anthracycline-containing regimens in immune restricted, “cold” tumours may be
effective for immune priming.
TRIAL REGISTRATION: Not applicable (non-interventional study). CRUK Internal Database Number 14232.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01599-0
INTRODUCTION
Breast cancer is a heterogeneous disease, encompassing multiple
molecular subtypes, some of which have targeted therapies
available, including endocrine therapy and anti-HER2 therapies for
oestrogen receptor-positive (ER+) and human epidermal growth
factor 2 positive (HER2+) disease, respectively. Despite this,
patients receiving chemotherapy are most frequently treated
with anthracycline-taxane containing regimens, regardless of
subtype. In the neoadjuvant setting, ~18% of unselected patients
will have a pathological complete response (pCR) to treatment,
although there is currently no reliable method of predicting this
[1]. Importantly, the highest response rates to DNA-damaging
agents, including anthracyclines, are seen in patients with DNA-
repair-deficient tumours. For example, BRCA1/2-mutant tumours
are more sensitive to DNA-damaging agents, including anthracy-
clines and carboplatin [2, 3]. However, anthracyclines have
important long-term toxicities, particularly cardiotoxicity, when
compared with non-anthracycline regimens [4, 5]. Furthermore,
the addition of trastuzumab to anthracycline-containing regimens
has been shown to substantially increase the incidence of
cardiotoxicity [6]. Finally, anthracycline-containing regimens are
associated with a small excess in cases of myelodysplasia and
acute myeloid leukaemia [7]. Given these toxicities, there is clearly
a pressing clinical need to identify patients likely to benefit from
DNA-damaging agents prior to treatment.
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Recently, we identified an immune-driven 44-gene signature
recognising the loss of the Fanconi Anemia (FA)/BRCA DNA-repair
pathway— the DNA Damage Immune Response (DDIR) signature
[8]. The assay was developed using DNA microarray data from
patients with FA and from breast tumours (enriched for BRCA1/2-
mutant-associated tumours). Unsupervised hierarchical clustering
allowed the identification of a subgroup of cases with an innate
DNA-repair deficiency, characterised by upregulation of a subset
of genes associated with immune signalling. In the retrospective
analysis, this 44-gene signature was developed and validated
across all breast cancer molecular subtypes to predict response to
DNA-damaging chemotherapy in both the adjuvant and neoadju-
vant treatment of breast cancer, predicting 5-year relapse-free
survival post-adjuvant treatment in DDIR-positive patients, with a
hazard ratio of 0.37 (95% CI 0.15–0.88, P= 0.03). Moreover, the
signature has been shown to be prognostic in triple-negative
breast cancer (TNBC), with DDIR positivity associated with
improved disease-free and overall survival in patients treated
with adjuvant doxorubicin/cyclophosphamide chemotherapy [9].
The DDIR-positive molecular subtype is characterised by the
upregulation of immune genes, including cytokines and immune-
checkpoint genes [8]. Using preclinical models, we demonstrated
constitutive activation of the cGAS-STING pathway in DNA-repair-
deficient tumours to be the underlying mechanism for this innate
immune response [10]. In keeping with this, breast tumours with a
high DDIR signature score are associated with increased tumour-
infiltrating lymphocytes (TILs) at diagnosis, including CD4+ and
CD8+ T lymphocytes [9, 10]. Activation of the cGAS/STING
pathway has been linked with the upregulation of immune-
checkpoint genes, which was also observed in DDIR-positive
breast tumours [8, 10]. Taken together, this suggests that DDIR-
positive tumours are characterised by an inflamed yet immune
restricted tumour microenvironment, where increased immune
infiltrates coexist with upregulated immune checkpointing genes.
In breast cancer, activation of an anti-tumour immune response
and the presence of TILs is linked with both increased pathological
complete response (pCR) rates and improved long-term outcomes
after neoadjuvant chemotherapy [11, 12]. Consequently, the DDIR
signature may identify a group of tumours characterised by
immune activation that respond to DNA-damaging chemother-
apy, potentially providing a predictive biomarker with clinical
utility in the neoadjuvant setting in early breast cancer.
The primary objective of this study was to prospectively
determine the feasibility of integrating the DDIR signature into
clinical workflows, with a report obtained within 14 days (judged
to be a realistic timeframe for the use of this novel, previously
validated biomarker in clinical decision-making). Secondary end-
points included the ability of the assay to predict response to
standard neoadjuvant chemotherapy (NACT) in the treatment of
early breast cancer. Gene expression profiling and histological
analysis of pre- and post-chemotherapy biopsies were performed
to identify immune responses and other potentially targetable




Patients with a histologically confirmed diagnosis of breast cancer suitable
for neoadjuvant treatment were recruited at two Northern Ireland centres
(Belfast City Hospital and Ulster Hospital, Dundonald) between April 2014
and August 2017. Women who were 18 years or older, WHO performance
status 0–1, with T1-3, N0-2 (AJCC 8th Edition) or inflammatory breast
cancer were eligible. Inclusion/exclusion criteria are outlined in Supple-
mentary Fig. 1. The study was approved by the Office for Research Ethics
Committee Northern Ireland (Reference: 13/NI/0107).
Tumour grade was identified on diagnostic biopsies. Biomarker status
(oestrogen receptor (ER), progesterone receptor (PR) and HER2) was
determined centrally; methods are described in Supplementary Materials.
Nodal status was assessed at diagnosis by axillary ultrasound+ /− fine
needle aspiration cytology. Pre-treatment sentinel lymph node biopsy
(SLNB) was carried out if axillary staging was negative; patients with nodal
involvement determined either by cytology or SLNB underwent axillary
lymph node dissection following neoadjuvant therapy at the time of
definitive breast surgery.
As the primary endpoint of the study was the feasibility of returning an
assay report within 14 days, an arbitrary sample size of 50 patients was
chosen; there was no formal power calculation for secondary or
exploratory endpoints. Details of statistical analysis are provided in
the Supplementary Materials.
Interventions
The trial schema is outlined in Supplementary Fig. 1A. Following informed
consent, two additional 14-G needle tumour biopsies, one formalin-fixed
paraffin-embedded (FFPE) and one fresh frozen (FF), were obtained.
Patients were treated according to local guidelines. All patients received
three cycles of FEC “100” (5-fluorouracil 500mg/m2, epirubicin 100mg/m2
and cyclophosphamide 500mg/m2 given intravenously q3 weeks) che-
motherapy and were then treated with three further cycles of FEC “100” or
taxane treatment with the addition of trastuzumab/pertuzumab concur-
rently with taxanes in HER2-positive tumours. No patients in this study
received platinum salts as this was not standard of care in these
institutions at the time of this study. Further FFPE biopsies/resection
specimens were taken at the time points indicated in Supplementary
Fig. 1A. DDIR scores were not reported to either treating clinicians or
patients and the report was not used to select treatment; patients received
standard of care neoadjuvant therapy, with the choice of regimen at the
discretion of their treating physician. Definitive breast surgery was carried
out within 4–6 weeks after the completion of systemic therapy.
Gene expression profiling
H&E sections were annotated for tumour content. A minimum estimated
tumour content of 80% viable tumour nuclei within the annotated area
was mandated. Following annotation, 10 × 6-µm sections were cut and
annotated tumour macrodissected for RNA extraction. cDNA microarray
profiling was performed using the Almac Breast DSA (Almac Diagnostic
Services, Craigavon, UK) as previously described, as this is the technology
on which the signature has been validated for clinical use [3]. For
exploratory analysis, to aid understanding of the underpinning biology,
RNA sequencing was performed on RNA extracted from pre- and post-
treatment FFPE specimens, using the Illumina Tru-Seq® RNA Exome library
preparation kit, followed by sequencing on the Illumina NextSeq with
paired-end reads (75 bp) and 50M reads per sample. Details of alignment
and expression calculation are provided in Supplementary Material.
Determination of DDIR score
Microarray data were pre-processed using the Robust Multi-array Average
(RMA) method [13], as previously described [8]. The median expression of
each of the DDIR genes was determined and DDIR score was calculated
based on the weighted sum of these genes. A previously published, pre-
defined threshold of 0.3681 was used to define DDIR signature status,
whereby a score ≥0.3681 was classified as DDIR positive and <0.3681
classified as DDIR negative [8].
Assessment of pathological response
Surgical resection was performed within 4–6 weeks of the final cycle of
NACT. Pathological response rates were measured on resection specimens
using Residual Cancer Burden (RCB) scores [14]. RCB was assessed as 0, 1, 2
or 3 where 0 refers to pathological complete response (AJCC ypT0/ypTis
ypN0) and 3 to extensive residual disease. RCB scoring was reported as this
is a validated measure of response to therapy and is recommended for use
in neoadjuvant chemotherapy trials [15]. Pathologists were blinded to the
DDIR score.
Identification and quantification of TILs
Tumour-infiltrating lymphocytes (TILs) were defined as the percentage of
stromal TILs within the margins of the tumour. These were scored as a
continuous percentage and reported in accordance with the recommen-
dations of the International Immuno-Oncology Working Group on Breast
Cancer for both baseline and residual tumour specimens. [16, 17]. TILs
were scored by two independent observers on 4-μm haematoxylin and
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eosin (H&E) sections of biopsy samples taken at diagnosis, after three
cycles of NACT and at surgical resection. Observers were blinded to DDIR
and RCB scores. Good concordance was identified between observers with
a 78.48% agreement (Cohen’s kappa co-efficient= 0.536).
claraT total mRNA report
The raw sequence data in FASTQ format were normalised to FPKM data
matrices and processed through Almac’s proprietary analysis pipeline and
reporting software for generation of the Version 2.0.0 claraT Total mRNA
Report (Almac Diagnostic Services, https://www.almacgroup.com/
diagnostics/claratreport/). claraT is a software-driven solution, classifying
biologically relevant gene expression signatures into several text and
graphical reports. Version 2.0.0 claraT Total mRNA Report, reports on six key
biologies (Immuno-Oncology (IO), Epithelial to Mesenchymal Transition
(EMT), Angiogenesis, Proliferation, Cell Death & Genome Instability) by
providing expression of 62 unique gene expression signatures, 60 single
gene drug targets and 3952 single genes relevant to the six biologies for
exploratory analysis. Further detail on claraT is provided in the Supplemen-
tary Material.
Multiplex immunofluorescence staining
Sequential 3-µm sections were obtained from FFPE tumour blocks. Serial
sections were stained with two previously validated multiplex panels
conducted using Opal 7-Color Automation IHC Kit (Akoya Biosciences,
Marlborough, MA, USA) [18]. Details of the panels are provided
in Supplementary Materials. Automated staining was conducted on a
Leica Bond Rx. Optimised retrieval methods and sequential staining steps
for Opal are detailed in Supplementary Table 1 and were used according to
the manufacturer’s instructions. Image analysis details are provided
in Supplementary Materials.
RESULTS
Trial enrolment and DDIR scores
Trial enrolment is summarised in Supplementary Fig. 1B. Fifty-two
patients were recruited, with one withdrawal and two patients
excluded (shown in the CONSORT flow diagram). Three diagnostic
biopsy samples (6.1%) contained insufficient tumour content for
RNA extraction, leaving 46 patients for analysis. DDIR signature
results were available within 14 days for 45 patients (97.8%).
Figure 1a shows patient and tumour characteristics at an
individual patient level. Table 1 summarises patient/tumour
pathological characteristics, treatment regimens given and
pathological response to treatment, according to DDIR status.
Twenty-six patients had DDIR-positive tumours, and 20 DDIR
negative. Tumour grade was higher in DDIR-positive tumours (on
baseline assay score) compared to DDIR-negative (P= 0.02). Other
clinicopathological characteristics, including ER/PR and
HER2 status, as well as lymph node involvement, were similar
between DDIR-positive and negative tumours (P values in Table 1).
DDIR assay predicts response to NACT
Patients with DDIR-positive tumours had an odds ratio of 4.667 for
either complete pathological response to NACT, or minimal
residual disease (MRD) (RCB 0–1) (95% CI 1.131–15.09, P=
0.0324). Only 4 out of 20 patients with DDIR-negative tumours had
a pathological response to treatment (RCB 0–1), in comparison to
14 out of 26 DDIR-positive tumours. Tumours with RCB 2 or 3
(moderate or extensive residual disease post NACT) had sig-
nificantly lower DDIR scores (median 0.2607) than RCB 0–1
(median 0.4636) compared individually (P= 0.0286 and 0.0042,
respectively) or collectively (P= 0.0033) (Fig. 1b, c). Similarly,
tumours with a pathological complete response (pCR, RCB 0) to
NACT had significantly higher DDIR scores than those with any
residual disease (RCB 1–3) (P= 0.0152) (Supplementary Fig. 2).
Indeed, DDIR-positive tumours had an odds ratio of 6.60 (95% CI
1.334–32.27, P= 0.0217) for complete pathological response
(RCB 0) versus not (RCB 1-3). In multivariate analysis (Supplemen-
tary Table 2), DDIR status remained an independent predictor of
























































Fig. 1 Tumour characteristics and response to NACT according to DDIR status. a Tumour characteristics: each column represents one
patient. DDIR status is shown on the top row with the associated key. Hormone and HER2 receptor status are shown for each tumour, clinical T
and N stages and grade. RCB= residual cancer burden score where 0 = complete pathological response, 1 = minimal residual disease,
2 = moderate residual disease and 3 = extensive residual disease. No significant difference in patient characteristics was identified except for
grade, where DDIR-positive tumours were noted to be higher grade than those classified as DDIR negative (P= 0.024, unpaired t test, data in
Table 1). b DDIR score and RCB (response) to NACT. Tumours that demonstrated RCB 0–1 clinical response had significantly higher DDIR scores
than those with RCB 2–3 responses (*P= 0.0286, **P= 0.0042, unpaired t test, 46 cases). c Compared collectively, tumours with a clinical
response of RCB 0–1 to NACT had significantly higher DDIR assay scores than those with RCB 2–3 responses. (**P= 0.0033, unpaired t test, 46
cases).
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Tumour-infiltrating lymphocytes
As previously reported [10], increasing DDIR score correlated with
increased TILs (P= 0.0213, Spearman’s correlation, r= 0.3386)
(Fig. 2a). DDIR-positive tumours had significantly higher TIL levels
at baseline than DDIR-negative tumours (median TILs 20% vs 7.5%;
P= 0.0144) (Fig. 2b). However, comparison of baseline TILs in
responders to NACT (RCB 0–1) compared to tumours with
moderate/extensive residual disease (RCB 2-3) did not reveal a
significant difference (Fig. 2c) (P= 0.179). Similarly, no significant
difference was observed between TIL levels at baseline in patients
with a pCR, compared to those with any residual disease (P=
0.3453) (Supplementary Fig. 3A). In a multivariate analysis
including tumour grade, ER and HER2 status, DDIR status and
TIL levels, TILs were not seen to independently predict response to
treatment (Supplementary Table 2).
TIL levels were not significantly different between breast cancer
subtypes (Supplementary Fig. 3B). Changes in DDIR score before
and after three cycles of FEC-100 are shown for DDIR-negative
(Supplementary Fig. 4A) and DDIR-positive tumours (Supplemen-
tary Fig. 4B), showing, respectively, a non-significant rise and fall in
DDIR scores with treatment. Changes in TIL level during treatment
according to DDIR score status are shown in Supplementary
Fig. 5A and B with a significant reduction in TILS seen in DDIR-
positive tumours between baseline and surgery (P= 0.0254).
Supplementary Fig. 5C and D illustrates the changes in TIL levels in
DDIR-positive responding and non-responding tumours, demon-
strating significant reductions in TILs in DDIR patients with a
good response to treatment (P= 0.007). A non-significant increase
in TIL levels was seen in DDIR-negative tumours following
chemotherapy.
Strikingly, in patients with pCR or MRD (RCB 0–1), TILs were
absent or markedly reduced at the completion of NACT in
resection specimens (P= 0.0072) (Fig. 2d). In comparison, in non-
responding tumours, TILs showed a non-significant rise following
three cycles of FEC chemotherapy (Fig. 2d), in keeping with the
observation that anthracyclines are immune stimulants [19–21].
Non-responding tumours were noted to have persistent lympho-
cytic infiltrate at resection (Fig. 2d).
Immune cell populations and signalling in DDIR-negative and
-positive tumours
Transcriptomic data from baseline tumour biopsies were used to
identify immune infiltrating populations in both DDIR-negative
and -positive tumours, using previously described, well-validated
gene signatures [22, 23]. Signature scores representing adaptive
immune-response cells (B and T lymphocytes) were significantly
higher in DDIR-positive compared to DDIR-negative tumours
(Fig. 3a). Notably, signatures representative of exhausted T cells
were also higher in DDIR-positive breast tumours (P < 0.001). We
then identified innate immune populations in DDIR-negative and
Table 1. Clinicopathological characteristics of study patients.
All patients DDIR-positive DDIR-negative
(n= 46) (n= 26) (n= 20)
Age at diagnosis (years) 28–64 35–64 28–58 P= 0.813a
(median= 47) (median= 47) (median= 48)
ER-positive HER2-negative 27 (59%) 13 (48%) 14 (52%) P= 0.41b
HER2-positive (n) 16 (35%) 9 (56%) 7 (44%)
ER+ HER2+ 11 (24%) 5 (45%) 6 (55%)
ER− HER2+ 5 (11%) 4 (80%) 1 (20%)
Triple-negative 13 (28%) 8 (62%) 5 (38%)
T stage P= 0.37c
T2 27 17 (63%) 10 (37%)
T3 19 9 (47%) 10 (53%)
N P= 0.23c
Neg 12 5 (42%) 7 (58%)
Pos 34 21 (62%) 13 (38%)
Grade P= 0.02b*
2 14 4 (29%) 10 (71%)
2/3 6 3 (50%) 3 (50%)
3 26 19 (73%) 7 (27%)
Treatment regimen P= 0.35c
FEC 100 8 3 (37%) 5 (63%)
FEC-taxane 38 23 (61%) 15 (39%)
Neoadjuvant anti-HER2-targeted treatment 13 5 (38%) 8 (62%)
Pre-treatment SLNB 16 8 8 P= 0.57c
SLNB +ve 4 3 (75%) 1 (25%)
SLNB −ve 12 5 (42%) 7 (58%)
RCB class P= 0.03c*
RCB0-1 18 14 (78%) 4 (22%)
RCB2-3 28 12 (43%) 16 (57%)
aMann–Whitney test.
bChi-squared test (*P < 0.05).
cFisher’s exact test (*P < 0.05).
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-positive tumours (Fig. 3a). While again most signature scores
representing innate immune cell populations were significantly
higher in DDIR-positive cancers compared to DDIR-negative
cancers pre-treatment, mast cell signature scores were lower in
DDIR-positive tumours (P < 0.05). Importantly, mast cells have
been associated with increased angiogenesis in a number of solid
tumours [24]. In addition, signature scores representing macro-
phages were higher in DDIR-positive tumours (P < 0.001), and this
finding was confirmed across breast cancer subtypes with
immunohistochemical staining for CD68 (Fig. 4). Furthermore,
despite overall levels lower of CD68 expression, the low levels of
CD8 expression also seen in DDIR-negative tumours resulted in
higher CD68/CD8 gene expression ratios, implying these tumours
had a higher proportion of “M2” polarised macrophages (which
have been associated with an immunosuppressive tumour
microenvironment (TME) [25], compared to DDIR-positive tumours
(Fig. 3a). This finding was validated at the protein level using
multiplex fluorescence immunohistochemical staining for CD8+
and CD68+ infiltration in tumour core biopsies, (Fig. 4). As
expected, CD8 positivity was significantly higher in DDIR-positive
than negative tumours (median CD8 positivity 12.3% vs 6.24%,
P= 0.037), as was CD68 positivity (median 4.33% vs 0.955%, P=
0.029) (Supplementary Fig. 6).
We also utilised the molecular signatures database (MSigDB)
scoring system [26] to assess immune hallmarks within tumours.
This identified upregulation of interferon-alpha and gamma,
complement and IL2-STAT5 signalling pathways in DDIR-positive
tumours (P < 0.001) (Fig. 3a). Interestingly, a significant increase in
transforming growth factor-beta (TGF-β) signalling (P < 0.05) was
identified in DDIR negative tumours, in keeping with immune
exclusion in this subgroup of breast tumours [27].
Immune-checkpoint gene expression is upregulated in DDIR-
positive tumours
The immune-checkpoint genes PD-L1 (CD247), CTLA4, LAG3, TIM3
(HAVCR2) and IDO1 were assessed using gene expression data,
with significantly higher expression of each in DDIR-positive
tumours (Fig. 3a). Multiplex immunofluorescence (IF) for PD-L1
and CD68 in DDIR-positive tumours confirmed that the majority of
the PD-L1 expression co-localised with macrophages (Fig. 4). In the
transcriptomic data, normalised PD-L1 expression has been shown
to correlate with the Prat macrophage-infiltration signature
(Supplementary Fig. 7A, Spearman correlation, r= 0.7869, P <
0.0001). This was confirmed at the protein level, using the
multiplex IF data to correlate CD68 and PD-L1 expression

































































































Fig. 2 Tumour-infiltrating lymphocytes and response to NACT. a Correlation between DDIR score and tumour-infiltrating lymphocytes
(TILs). An increasing percentage of stromal TILs correlates with increasing DDIR score. Dotted line shows threshold for DDIR negative/positive
cut-off (r= 0.3386, P= 0.0213, Spearman correlation, 46 evaluable cases). b DDIR-positive tumours had significantly increased lymphocytic
infiltration at baseline compared to tumours classified as DDIR negative. (*P= 0.0144, unpaired t test, 46 evaluable cases). c Percentage
stromal TILs at baseline according to response to NACT using RCB score. No significant difference in TILs was identified in tumours with RCB 0
or 1 (median 10%) compared to RCB 2 or 3 (median 5%) responders. (P= 0.123, unpaired t test, 46 evaluable cases). d (i) Response to NACT
was associated with reduced TILs at resection compared to baseline. (P= 0.0072, unpaired t test, 15 paired samples). (ii) No significant
difference in TILs between baseline and resection was seen in non-responding tumours, with a non-significant increase noted following three
cycles of FEC. (P= 0.0792, unpaired t test, 22 paired samples).
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Together with the data above, this suggests that DDIR-positive
tumours maintain tumour growth in the presence of immune
infiltration via upregulation of immune checkpoints, with the
macrophage population a key contributor to the upregulation of
PD-L1.
We assessed a further six gene signatures [28–30] associated
with immune infiltration and potential response to immune-
checkpoint blockade (ICB). All signature scores were significantly
higher in DDIR-positive tumours (Fig. 3b). However, gene
signatures associated with predicted resistance to ICB and
fibroblast response [31–33] did not show a significant difference
between DDIR-negative and -positive tumours (Fig. 3b).
In summary, DDIR-positive tumours showed increased immune
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expected, PD-L1 and IDO1 expression were elevated in DDIR-
positive tumours, given that these genes are constituent parts of
the signature; however, upregulation of non-signature checkpoint
genes was also seen in the transcriptomic data. In contrast, DDIR-
negative tumours have a paucity of immune cell infiltration, with
increased TGF-β signalling.
Identification of potentially targetable biologies in DDIR-
negative tumours
In addition, we identified upregulation of angiogenic signalling in
DDIR-negative tumours, which is in keeping with the high mast
cell signature scores observed in these tumours [34–36] (Fig. 3b).
In addition, as TGF-β signalling was increased in DDIR-negative
tumours, we asked if there was concomitant upregulation of
epithelial–mesenchymal transition (EMT). Indeed, we observed
higher EMT signalling in DDIR negative, relative to DDIR-positive
tumours [26, 37–39] (Fig. 3b).
While each signature correlated strongly with others predicting
similar biology, there was a marked inverse correlation between
signatures associated with increased angiogenesis and EMT
signalling and those associated with immune response (Fig. 3c).
The subgroup correlation for DDIR-positive and DDIR-negative
tumours is shown in Supplementary Fig. 8. For signatures reported
to predict resistance to ICB, there was a strong correlation with
those predicting increased angiogenesis and EMT signalling.
Therefore, DDIR-negative tumours with strong angiogenic or
EMT signalling were associated with poor responses to NACT.
Immune responses are induced by DNA-damaging
chemotherapy
Biopsy samples were obtained after three cycles of FEC
chemotherapy in a subset of 32 patients. Of these, 12 contained
inadequate tumour (<20% tumour content) for RNA extraction. A
further three samples failed QC following RNA extraction, leaving
17 samples suitable for subsequent gene expression profiling. Of
these, 15 had an RCB 2–3 response to NACT: 8 DDIR-negative
tumours and 7 DDIR positive. As expected, tumour content was
low in post-FEC samples from tumours that responded to NACT
(RCB 0–1). Immune cell populations were analysed as before in
baseline and post-FEC-treated samples. DDIR-negative tumours
demonstrated an increase in infiltration of adaptive immune-
response cells (Fig. 5a, P= 0.00246), although there was no
notable increase in gene expression signatures identifying innate
immune populations (Fig. 5a, P= 0.168). A marked increase in
immune biologies, in particularly increased interferon α and γ, and
interferon activation was identified (P < 0.001), with a trend
towards reduced TGF-β signalling following NACT (Fig. 5b,
P= 0.090). Gene expression signatures predicting response to
ICB also significantly increased following three cycles of DNA-
damaging chemotherapy in these tumours (Fig. 5c, P < 0.001).
Importantly, in DDIR-negative tumours, there was increased
immune-checkpoint gene expression following FEC, although this
increase only reached statistical significance for PD-L1 (Fig. 5d). No
significant changes were seen in immune gene expression before
and after FEC treatment in DDIR-positive tumours (Supplementary
Fig. 9).
Defining characteristics of DDIR-positive responders and non-
responders to NACT
No significant differences in clinicopathological characteristics
between DDIR-positive tumours with an RCB 0–1 response compared
to those with RCB 2–3 were identified, although this did approach
significance for breast cancer subtype (P= 0.051) (Supplementary
Table 3, P values in table). Comparison of immune-response
signatures in DDIR-positive non-responders (RCB 2–3) and responders
(RCB 0–1) did not identify any differences in signature scores (Fig. 3a).
There were also no significant differences between angiogenesis and
EMT signature scores in DDIR assay-positive non-responders and
responders (Fig. 3b; P values in Supplementary Table 4, 4A, B).
To address why some tumours with an active immune response
at baseline and predicted DNA-repair deficiency did not respond
to NACT, we analysed gene expression signatures associated with
genomic instability, proliferation, and cell death, comparing non-
responders to responders (Supplementary Fig. 10). There was a
trend to higher proliferation and cell death signature scores in
responding tumours. Signatures associated with genomic instabil-
ity, including aneuploidy and chromosomal instability, were also
higher in responding tumours. However, no clear resistance
mechanisms to NACT in these non-responding immune-active
tumours were identified.
DISCUSSION
As outlined above, similar cytotoxic chemotherapy regimens are
used to treat breast cancer, regardless of molecular subtype.
Despite the evidence that tumours with a DNA-repair pathway
deficiency are likely to respond better to DNA-damaging agents
(such as anthracyclines), there is no good biomarker in clinical use
to predict response to treatment. The DDIR signature was
developed using microarray data from BRCA1/2-deficient, DNA-
repair-deficient tumours with the specific aim of identifying such
tumours. Here, we have demonstrated that the 44-gene DDIR
signature can predict response to neoadjuvant chemotherapy in
unselected early breast cancer patients, across molecular sub-
types. Although germline BRCA1/2 mutation status is unknown in
this cohort, the design of the signature means that any BRCA-
associated cancers will likely be identified as DDIR positive due to
their intrinsic DNA-repair deficiency. Furthermore, this feasibility
study has clearly demonstrated that the assay can be incorporated
into clinical workflows in a timely manner, allowing its adoption
into practice.
In recent years, there has been a suggestion that not all breast
cancer patients require anthracycline treatment, although there
remains a paucity of biomarkers to identify patients likely to
benefit from these agents [40]. The findings from this study, taken
together with the previous clinical and preclinical studies, suggest
Fig. 3 Immune signalling, angiogenesis and EMT in DDIR-negative and -positive tumours. a Panels 1 and 2 = Gene signatures predicting
acquired (panel 1) and innate (panel 2) immune cell infiltrating populations in DDIR-negative (left) and DDIR-positive (right) tumours; ex
T cells exhausted T cells, DC dendritic cells, NK natural killer cells. Panel 3=macrophage polarisation. Panel 4= Immune signalling
pathways identified as active in DDIR assay-positive and -negative tumours. Panel 5 = Expression of immune-checkpoint genes in DDIR-
negative and positive tumours. DDIR status and RCB score (0–3) is indicated on x axis for all 46 samples. *P < 0.05; **P < 0.01; ***P < 0.001,
unpaired t test. b Panel 1=Gene signatures derived from claraT analysis and reported to predict response to immune-checkpoint blockade, as
well as the DDIR assay [8, 28–30, 58–60]. Panel 2= Gene signatures derived from claraT analysis and reported to predict resistance to ICB in
DDIR-negative and -positive tumours [27, 31–33]. Panel 3= Gene signatures associated with increased angiogenic signalling or response to
anti-angiogenic agents [34–36, 61]. Panel 4=Gene signatures associated with increased EMT signalling [26, 37–39, 62]. DDIR status and RC
score (0–3) is indicated on x axis for all 46 samples. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired t test. c Correlations of gene signatures
predicting angiogenic, EMT or immune signalling. Signatures predicting angiogenic or EMT signalling negatively correlated with those
predicting immune signalling. Significance of correlation is shown using size, red indicates a positive correlation and blue negative correlation
(gene signature references as for Fig. 4b).
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that there may be a subgroup of tumours with high sensitivity to
anthracycline-containing chemotherapy where anthracycline-
sparing regimens should not be considered. Conversely, the
signature may also have utility in identifying those patients
unlikely to benefit from anthracycline-based chemotherapy (such
as FEC or AC), such that these could be omitted to minimise
cardiotoxicity and the risk of haematological malignancy. Valida-
tion of this hypothesis would however require a direct comparison
of anthracycline versus non-anthracycline regimens by DDIR
status.
Other studies have reported associations between DNA-repair
deficiency and immune infiltration [41–43]. In line with this, the
DDIR signature identifies a molecular subgroup of tumours
characterised by upregulated immune signalling. In keeping with
this, we have shown that DDIR-positive tumours display increased
immune infiltration, including both adaptive and innate immune
cell populations, compared with DDIR negative tumours. This is
consistent with our preclinical data showing that DNA-repair
deficiency leads to the presence of cytosolic double-stranded
DNA, which is sensed by cGAS, resulting in STING activation and a
type I interferon-like response [10]. Importantly, as supported in
this clinical study, activation of this pathway is also associated with
upregulation of immune-checkpoint gene expression including
PD-L1, CTLA4 and IDO1 [10, 21].
In this study, we have shown a correlation between DDIR score
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Fig. 4 T-cell/macrophage expression and PD-L1/macrophage expression across breast cancer subtypes, by DDIR status. From top to
bottom, luminal, HER2-positive and triple-negative breast cancer (TNBC) cases are illustrated and have been stained for cytokeratin (red),
CD68 macrophages (yellow), CD8 T cells (white) and PD-L1 immune-checkpoint protein (green) expression. DDIR-positive cases are shown on
the left and DDIR-negative cases on the right, illustrating higher CD68 and CD8 expression in DDIR-positive tumours, and co-localisation of
PD-L1 and CD68 in DDIR-positive cases. All images are shown at ×4 magnification.
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DDIR scores to be associated with higher TIL density in a cohort of
TNBC patients [9]. TILs have previously been shown to be a
prognostic factor in TNBC treated with adjuvant chemotherapy
[44]. Furthermore, TILs have been shown to predict pCR in the
neoadjuvant setting, albeit with longer-term prognostic value only
in HER2+ and TN subtypes [45]. Although we did see higher TIL
levels in patients with RCB 0-1 disease compared with RCB 2-3, this
finding, unlike the predictive value of DDIR score, did not reach
significance. Given that DDIR and TILs have previously been
shown to be moderately correlated, it is possible that the ability of
TILs to predict pCR in this series is not evident due to the relatively
small number of patients included in the series and the fact that
they represent all molecular subtypes of disease including luminal
cancers. However, the fact that in a small series the DDIR assay is
predictive of pCR suggests that this signature provides an
objective measure of the biological processes underlying the
presence of TILs and thus may have clinical utility across molecular
subtypes in breast cancer.
Taken together, this suggests that DNA-repair deficiency/DDIR
positivity results in an immune infiltrate which is functionally
restricted via upregulation of immune checkpoints. Nonetheless,
in this study, DDIR-positive tumours were more likely than DDIR
negative tumours to respond to neoadjuvant treatment with
regimens containing DNA-damaging agents, presumably due to
an intrinsic DNA-repair pathway defect. Importantly, we and
others have shown that DNA-damaging agents also induce
cytosolic dsDNA and cGAS-STING activation in DNA-repair
proficient models [10, 41, 46]. Indeed, we recently carried out
an in vitro screen of multiple chemotherapeutic agents for their
ability to induce cytosolic dsDNA, identifying anthracyclines as
potent cGAS-STING activators [21]. In keeping with this,
anthracyclines also induced immune-checkpoint gene expres-
sion, suggesting that anthracyclines may be considered as the
preferred combination chemotherapy for ICB. The TONIC trial
previously confirmed these preclinical findings in the setting of
metastatic TNBC, where induction with low-dose doxorubicin
was identified as superior to other DNA-damaging agents in
promoting responses to ICB [19]. In our study, we have shown
that in a small number of immune “cold” tumours (DDIR-
negative, n= 8), FEC treatment led to increased TILs (albeit a
non-significant increase), with significant enrichment of adap-
tive immune cell populations identified by immune-related gene
signatures. Although this represents a small sample, taken in
conjunction with other data, this leads us to hypothesise that
treatment with chemotherapy regimens containing anthracy-





























































































Fig. 5 Immune gene expression pre- and following three cycles FEC NACT in DDIR-negative tumours (eight paired samples). a Predicted
immune cell populations in baseline tumour biopsies and post-FEC in DDIR-negative tumours where blue indicates gene expression score
pre-treatment and red following three cycles of FEC chemotherapy. *P < 0.05, **P < 0.01. b Upregulation of immune signalling pathways post-
FEC in DDIR-negative tumours. *P < 0.05, **P < 0.01. c Signature scores: upper panel: signatures reported to predict response to ICB. Lower
panel: signatures reported to predict resistance to ICB and an inflamed microenvironment are shown in the lower panel. *P < 0.05, **P < 0.01.
d Gene expression of immune checkpoints at baseline and following three cycles FEC chemotherapy in DDIR negative tumours. *P < 0.05,
**P < 0.01.
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resulting in higher expression of signatures of the immune
response, immune-checkpoint gene expression and immune
infiltrates in DDIR negative, immune cold tumours. However,
presumably due to an intact DNA-repair pathway, these tumours
are less susceptible to DNA-damaging agents and therefore are
less likely to exhibit a pCR in this context, unlike DDIR-positive
tumours, where there is an innate DNA-repair pathway
deficiency as identified by the signature (which was developed
from patients and tumours with an innate repair pathway
deficiency. The transcriptomic findings from the current study,
taken together with data from the TONIC trial, suggest that
immune induction followed by ICB may be an effective
treatment strategy in immune restricted tumours. In contrast
to TONIC, which assessed low-dose therapy for immune
induction in the context of pre-treated metastatic triple-
negative disease, our study evaluated therapeutic doses of
anthracycline-containing regimens in treatment-naïve early
breast cancer across molecular subtypes. Further work is
required to define the optimal class, dose, and scheduling of
induction agents to activate the cGAS-STING pathway by this
mechanism and thus to achieve optimal responses to ICB.
There are several studies published evaluating the role of
immune-checkpoint blockade in the neoadjuvant setting in early
breast cancer, all in triple-negative disease. Both the IMPASSION-
031 and KEYNOTE-522 studies combined ICB (atezolizumab and
pembrolizumab respectively) with a backbone of anthracycline-
taxane chemotherapy and demonstrated an increase in pCR rates
with chemotherapy plus ICB when compared with chemotherapy
alone (58% vs 41% in IMPASSION-031, and 65% vs 51% in
KEYNOTE-522 [47, 48].
Taxanes alone, however, do not cause immunogenic cell death
or T-cell activation [49]. While cGAS promotes apoptosis following
taxane treatment, cGAS activation in this context does not result
in an interferon response [50]. Indeed, our preclinical modelling
suggests that taxanes, given in combination with anthracyclines,
may suppress cGAS-STING activation via blocking the formation of
anthracycline-induced cGAS-activating micronuclei [21]. In keep-
ing with this, in our study, some tumours which initially had an
increase in TILs following FEC did not maintain this through
taxane treatment, with a subsequent fall in TILs seen at the time of
resection, albeit this was only a trend, and did not reach statistical
significance. Interestingly, in this context, the NeoTRIP trial in the
neoadjuvant setting in early TNBC evaluated nab-paclitaxel in
combination with carboplatin+ /− atezoluzimab (and did not
have an anthracycline component to the chemotherapy back-
bone) and showed no significant improvement in pCR rates for
the ICB arm (43.5% vs 40.8%) [51].
Taken together, our data and that from the clinical trials
discussed above suggests the possibility that immune priming
may be more effective using anthracycline-based therapy rather
than taxanes as a combination strategy, and this is further
supported by recently published data [52]. Furthermore, given
that the DDIR signature identifies patients with upregulation of
immune checkpointing genes, it is possible that this biomarker
may be able to identify patients who will respond to ICB. Given the
limitations of PD-L1 staining as a biomarker with clinical utility,
there is a clear unmet need for a validated biomarker to predict
response to immuno-oncological therapeutic strategies. Patients
in this study did not receive any treatment with ICB; however, in
light of the DDIR signature’s potential to act as a biomarker in this
context, further validation in a cohort of patients treated with both
neoadjuvant chemotherapy and ICB is merited.
Furthermore, it has also been suggested that in BRCA1-deficient
TNBC, PARP inhibitors may induce CD8+ T-cell infiltration through
the cGAS/STING pathway [53]. Consequently, the DDIR signature
may also identify a group of tumours with a DNA-repair pathway
defect that might benefit from the use of PARP inhibitors or
PARPi/ICB combinations.
When considering the DNA-repair proficient, DDIR-negative
tumours in this study, we identified increased mast cells, with
associated increased activation of angiogenesis, which may
contribute to the immune restricted TME observed around these
tumours. We also identified increased TGF-β signalling in these
tumours at baseline, which was maintained following FEC
chemotherapy. TGF-β is proposed to prevent an effective
response to ICB by actively excluding lymphocytes from the
TME and promoting T-cell exhaustion [27, 54]. This may suggest
that therapies targeting this pathway may enhance response to
ICB or chemotherapy in these patients. In keeping with increased
TGF-β signalling, gene signatures identifying an EMT phenotype
were higher in DDIR negative tumours. EMT signalling is
associated with the development of stem-cell-like features and
associated chemotherapy resistance in breast cancer [55].
Although EMT-targeting therapies in combination with che-
motherapy may have clinical utility [56], a key area of interest is
the potential of these agents, in particular TGF-β and focal
adhesion kinase (FAK) inhibitors, to synergise with ICB [27, 54, 57].
In conclusion, our study validates the DDIR biomarker as
predicting response to neoadjuvant chemotherapy in early breast
cancer. We have demonstrated the feasibility of utilising the DDIR
signature in clinical practice in a timely manner, consistent with its
use to make treatment decisions, meriting further large-scale
prospective study. In addition, in a small number of cases, we
report the induction of immune responses in DDIR negative,
immune “cold” breast tumours. Moreover, whilst approval of ICB
therapy in the clinical setting has thus far been limited to
advanced TNBC, we also observed FEC-induced immune signalling
in ER-positive and HER2-positive tumours. This suggests that the
combination of anthracycline-based chemotherapy together with
ICB in the treatment of early breast cancer may be a rational
treatment strategy. Finally, additional validation is required to
determine the ability of the signature to predict response to
immune-checkpoint therapy in breast cancer.
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